Elevance Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elevance Health (ELV).

Price Target Range — 9 Quarters

Analyst Consensus — 20 Analysts

14Buy

6Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$438Upside to Avg. PT+6.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$457→$469
Jul 17, 2026	Bernstein	Lance Wilkes	PT Raise	Outperform	$482→$488
Jul 17, 2026	Leerink Partners	Whit Mayo	PT Raise	Market Perform	$364→$395
Jul 16, 2026	RBC Capital	Ben Hendrix	PT Cut	Sector Perform	$439→$424
Jul 16, 2026	Wells Fargo	Stephen Baxter	PT Cut	Overweight	$492→$473
Jul 16, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$399→$455
Jul 16, 2026	Barclays	Andrew Mok	PT Cut	Overweight	$480→$457
Jul 16, 2026	Baird	Michael Ha	PT Raise	Neutral	$331→$393
Jul 14, 2026	TD Cowen	Ryan Langston	PT Raise	Buy	$400→$465
Jul 14, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$450→$475
Jul 13, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$391→$492
Jul 9, 2026	RBC Capital	Ben Hendrix	PT Raise	Sector Perform	$358→$439
Jul 7, 2026	Cantor Fitzgerald	Sarah James	PT Raise	Overweight	$400→$450
Jul 2, 2026	Bernstein	Lance Wilkes	PT Raise	Outperform	$424→$482
Jun 8, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$435→$465
Jun 8, 2026	JP Morgan	Lisa Gill	PT Raise	Overweight	$411→$476
Jun 4, 2026	B of A Securities	Kevin Fischbeck	PT Raise	Buy	$435→$460
Jun 4, 2026	Morgan Stanley	Erin Wright	PT Raise	Equal-Weight	$352→$404
Jun 1, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$375→$450
May 26, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$408→$480

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Elevance Health, Raises Price Target to $469

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $457 to $469.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

Leerink Partners analyst Whit Mayo maintains Elevance Health (NYSE:ELV) with a Market Perform and raises the price target from $364 to $395.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and lowers the price target from $439 to $424.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $492 to $473.

Benzinga Newsdesk

These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

Elevance Health Inc. (NYSE:ELV) reported strong Q2 results and raised full-year guidance. Analysts have adjusted price targets for ELV stock.

Avi Kapoor

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $399 to $455.

Benzinga Newsdesk

Elevance Health Inc

Elevance Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Elevance Health, Raises Price Target to $469

PRO
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

PRO
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

People Also Watch

People Also Watch

Elevance Health Inc

Elevance Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Elevance Health, Raises Price Target to $469

PROLeerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

PRORBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

PROWells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

PROGuggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Elevance Health, Raises Price Target to $469

PRO
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

PRO
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455